Health
AI in Biotech: CEO Clarifies Hype and Reality
The CEO of BigHat Biosciences discusses the role of artificial intelligence in drug development, addressing both its potential and limitations.
Coverage timeline — 1 article
STAT News
CEO of BigHat Biosciences, which designs antibody therapies using machine-learning, on how AI can, and cannot, help in drug development.
2026-05-26 08:30 UTC